【摘要】 目的利用高通量体外药敏技术探索晚期肺癌新型治疗方案。方法选取符合入组条件的晚期肺癌伴恶性胸水患者12例,知情同意后抽取大于300m L的胸水送于中科普瑞昇医学检验所,对肺癌细胞进行体外培养、纯化,再在高通量药物筛选平台上对相关药物作用于肺癌细胞后的活力进行检测,并计算抑制率。结果筛选剂量下对肺癌细胞敏感(抑制率>70%)的药物有19种,平均抑制率由高到低的排序为:华蟾素、AZD9291、阿霉素、拓扑替康、雷公藤等,其中检测出抑制率超过90%的药物有11种,有华蟾素、AZD9291、索拉菲尼、阿帕替尼等。有6例患者华蟾素的抑制率均在90%以上,拉帕替尼、索拉菲尼和阿霉素各2例,其余药物1例。结论高通量体外药敏检测技术可以为晚期肺癌患者的临床个体化治疗提供重要参考价值,值得临床推广。更多还原

【Abstract】 Objective Exploiting High-throughput in vitro susceptibility Technology to explore new treatment plan for advanced lung cancer. Methods 12 samples of advanced lung cancer with malignant pleural effusion were selected. Extract more than 300 m L of pleural effusion sent to the Prece Do pharmaceuticals Co.Ltd. Lung cancer cells were cultured、purified, and the activity of the relevant drugs on lung cancer cells was tested.At the same time calculate the inhibition rate. Results There were 19 drugs that were sensitive to lung cancer cells(inhibition rate> 70%) at screening doses, the average inhibition rate from high to low is: Cinobufagin, Regoratenib, Doxorubicin, Topotecan, Tripterine an so on. Among them, 11 kinds of drugs with more than 90% inhibition rate were detected, including Cinobufagin,AZD9291,Sorafenib, Apatinib and so on. Six cases of cinobufagin were more than 90% inhibition rate, Lapatinib, Sorafenib and Doxorubicin in 2 cases, the remaining drugs in 1 case. Conclusions High-throughput in vitro susceptibility technology can provide important reference value for clinical individualized treatment of patients with advanced lung cancer, which is worthy of clinical promotion.更多还原